# Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

Study · id `cardio:ct-nct01950819` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01950819](<https://clinicaltrials.gov/study/NCT01950819>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01950819

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2037 participants.

## Technical summary

Registry record NCT01950819. Randomized; no masking; primary purpose treatment. Start 2013-12-03 (actual); primary completion 2017-02-01 (actual). Results posted on 2019-01-30.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2037 participants (enrolled count; ClinicalTrials.gov record NCT01950819, source copy `cardio:ctgov-nct01950819-2019-01-30`, retrieved 2026-10-26)
- Started: 2013-12-03 (actual) (ClinicalTrials.gov record NCT01950819, source copy `cardio:ctgov-nct01950819-2019-01-30`, retrieved 2026-10-26)
- Primary completion: 2017-02-01 (actual) (ClinicalTrials.gov record NCT01950819, source copy `cardio:ctgov-nct01950819-2019-01-30`, retrieved 2026-10-26)
- Completion: 2018-01-17 (actual) (ClinicalTrials.gov record NCT01950819, source copy `cardio:ctgov-nct01950819-2019-01-30`, retrieved 2026-10-26)
- Results first posted: 2019-01-30 (ClinicalTrials.gov record NCT01950819, source copy `cardio:ctgov-nct01950819-2019-01-30`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Chile; Colombia; Croatia; Czechia; Egypt; France; Germany; Greece; India; Israel; Italy; Japan; Kuwait; Lebanon; Malaysia; Mexico; Netherlands; Norway; Philippines; Poland; Portugal; Russia; Saudi Arabia; Serbia; Singapore; Slovakia; Slovenia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Türkiye (ClinicalTrials.gov record NCT01950819, source copy `cardio:ctgov-nct01950819-2019-01-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01950819-2019-01-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
- Acronym: TRANSFORM
- Condition: End Stage Renal Disease (ESRD)
- Condition: Chronic Kidney Disease (CKD)
- Condition: Hemodialysis
- Condition: Renal Replacement Therapy
- Condition: Renal Transplantation
- Intervention (Biological): Induction therapy
- Intervention (Drug): Corticosteroids
- Intervention (Drug): EVR+rCNI
- Intervention (Drug): MPA+sCNI
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation (`cardio:pubmed-29752413`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study (`cardio:pubmed-31152476`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study (`cardio:pubmed-32633157`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study (`cardio:pubmed-34216395`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d3e9459e99db3ffe10e38db568dc2ef5e3f70d3edaa223de46eaeebc4914f835
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
